Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408795 | 0.91 | MET (0.43) | METCYP3A4 | |
| Hydrochloric Acid SCHEMBL3410194 | 0.90 | MET (0.42) | METCYP3A4 | |
| SCHEMBL3407414 | 0.82 | MET (0.42) | METCYP3A4 | |
| SCHEMBL2764593 | 0.82 | MET (0.63) | METCYP3A4 | |
| SCHEMBL2764245 | 0.81 | MET (0.59) | METCYP3A4 | |
| SCHEMBL3409436 | 0.81 | MET (0.46) | METCYP3A4 | |
| SCHEMBL3402315 | 0.78 | MET (0.68) | METCYP3A4 | |
| SCHEMBL3406824 | 0.76 | MET (0.43) | METCYP3A4 | |
| SCHEMBL2801802 | 0.75 | MET (0.79) | METCYP3A4 | |
| SCHEMBL2765384 | 0.73 | MET (0.56) | METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | MET 2/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.